Skip to main content

Advertisement

SpringerLink
Log in

Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines

  • Clinical Guides in Oncology
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

While hepatocellular carcinoma (HCC) is a relatively common tumour with an annual incidence in the EU of 8 cases/100,000 inhabitants, bile tract carcinoma (BTC) is much less common, with an incidence of 4 cases per 100,000 inhabitants per year. In both cases, when planning treatment it is essential to perform accurate staging, evaluate hepatic functional reserve and performance status, and obtain the opinion of the patient. The only curative treatment is surgery. However, several interventional radiological techniques can help to achieve local disease control and the alleviation of symptoms. In addition, sorafenib (HCC) and chemotherapy (BTC) may contribute to prolong survival in patients with disseminated disease. Therefore, the therapeutic strategy should always be discussed and planned within a multidisciplinary tumour board.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ferlay J, Parkin DM, Pisani P (2010) GLOBOCAN 2009:cancer incidence and mortality worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer, Lyon, France. http://globocan.iarc.fr

    Google Scholar 

  2. Zhang BH, Yang BH, Tang ZY (2004) Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417–422

    PubMed  Google Scholar 

  3. Forner A, Ayuso C, Real MI et al (2009) Diagnosis and treatment of hepatocellular carcinoma. Med Clin 132:272–286

    Article  Google Scholar 

  4. Jelic S, Sotiropoulos GC (2010) Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21[Suppl 5]:v59–v64

    Article  Google Scholar 

  5. NCCN (2010) Hepatobiliary Cancers. NCCN Practice Guidelines in Oncology v.1.2010

  6. Bruix J, Sherman M (2005) Management of hepatocellular carcinoma. Hepatology 42:1208–1236

    Article  PubMed  Google Scholar 

  7. Dong J, Roberts LR (20100 Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7:448–458

    Google Scholar 

  8. Llovet J, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329–338

    Article  PubMed  CAS  Google Scholar 

  9. Forner A, Reig ME, Rodríguez-Lope C et al (2010) Current strategy for staging and treatment: the CCLC update and future prospects. Semin Liver Dis 1:61–74

    Article  Google Scholar 

  10. Thomas MB, Jaffe D, Choti MM et al (2010) Hepatocellular carcinoma: consensus recomendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 28:3994–4005

    Article  PubMed  Google Scholar 

  11. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  PubMed  CAS  Google Scholar 

  12. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34

    Article  PubMed  CAS  Google Scholar 

  13. Peck-Radosavljevic M, Greten TF, Lammer J et al (2010) Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 22:391–398

    Article  PubMed  CAS  Google Scholar 

  14. Eckel F, Brunner T, Jelic S (2010) Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol [Suppl 6]:v65–v69

  15. Aljiffry M, Wlash MJ, Molinari M (2009) Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990–2009. World J Gastroenterol 15:4240–4262

    Article  PubMed  CAS  Google Scholar 

  16. Blechacz B, Gores GJ (2008) Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48:308–321

    Article  PubMed  CAS  Google Scholar 

  17. Miyakawa S, Ishihara S, Takada T et al (2008) Flowchart for the management of biliary tract and ampullary carcinomas. J Hepatobiliary Pancreat Surg 15:7–14

    Article  PubMed  Google Scholar 

  18. Mosconi S, Beretta GD, Labianca R et al (2009) Cholangiocarcinoma. Crit Rev Oncol Hematol 69:259–270

    Article  PubMed  Google Scholar 

  19. Glimelius B, Hoffman K, Sjöden PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600

    PubMed  CAS  Google Scholar 

  20. Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273–1281

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Department, Hospital Universitario La Paz (IdiPAZ), RETICC, P. de la Castellana, 261, ES-28046, Madrid, Spain

    Jaime Feliu

  2. Medical Oncology Department, Hospital Clínico Universitario, RETICC, Madrid, Spain

    Javier Sastre

  3. Medical Oncology Department, Hospital Clinic de Barcelona, RETICC, Barcelona, Spain

    Joan Maurel

  4. Medical Oncology Department, Hospital Lozano Blesa, Zaragoza, Spain

    Dolores Isla

Authors
  1. Jaime Feliu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Sastre
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joan Maurel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dolores Isla
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jaime Feliu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Feliu, J., Sastre, J., Maurel, J. et al. Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. Clin Transl Oncol 13, 536–544 (2011). https://doi.org/10.1007/s12094-011-0694-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-011-0694-x

Keywords

Search

Navigation